Pediatrix Medical Group, Inc.

NYSE:MD Stock Report

Market Cap: US$892.4m

Pediatrix Medical Group Management

Management criteria checks 3/4

Pediatrix Medical Group's CEO is Jim Swift, appointed in Jan 2023, has a tenure of 1.67 years. total yearly compensation is $2.24M, comprised of 29% salary and 71% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $1.80M. The average tenure of the management team and the board of directors is 2.7 years and 4.2 years respectively.

Key information

Jim Swift

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage29.0%
CEO tenure1.7yrs
CEO ownership0.2%
Management average tenure2.7yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Aug 07
Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Jun 19
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

May 10
Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Mar 29
Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 10
Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Dec 25
Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Nov 14
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Oct 13
Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Aug 09
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Aug 08

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

Jul 03
At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Jun 08
The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Apr 26
Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Feb 20
Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Pediatrix Medical Group Q4 2022 Earnings Preview

Feb 16

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Jan 12
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Dec 22

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Dec 20
Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Pediatrix appoints James Swift as chief executive officer

Dec 15

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Nov 05
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Nov 03

Pediatrix: These 5 Graphs Suggest It's A Buy

Sep 29

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Sep 13
Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Aug 29
Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Jul 27
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix: Seeking 46% Return Objective As Speculative Buy

Jul 14

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 24
MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

May 25
MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

Apr 20
Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 08
MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Feb 15
MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Jan 19
Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?

Nov 17
Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?

These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well

Oct 23
These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Oct 08
Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

CEO Compensation Analysis

How has Jim Swift's remuneration changed compared to Pediatrix Medical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$252m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$650k

-US$60m

Sep 30 2023n/an/a

US$88m

Jun 30 2023n/an/a

US$95m

Mar 31 2023n/an/a

US$98m

Dec 31 2022US$1mUS$450k

US$63m

Compensation vs Market: Jim's total compensation ($USD2.24M) is below average for companies of similar size in the US market ($USD3.29M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


CEO

Jim Swift (62 yo)

1.7yrs

Tenure

US$2,237,839

Compensation

Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...


Leadership Team

NamePositionTenureCompensationOwnership
James Swift
CEO & Director1.7yrsUS$2.24m0.20%
$ 1.8m
C. Richards
Executive VP & CFO4yrsUS$1.78m0.21%
$ 1.9m
Mary Ann Moore
Executive VP1.9yrsUS$1.83m0.19%
$ 1.7m
John Pepia
Senior VP & Chief Accounting Officer8.3yrsUS$1.43mno data
Cheryl VanPatten
Senior VP & Chief Information Officer2.7yrsno datano data
Daniel Corcoran
Senior Vice President of Administration & Managed Careno datano datano data
Charles Lynch
Senior VP of Financeno datano datano data
Meghan Lublin
Senior VP3.1yrsno datano data
Mike Ashford
President of Regional Operations (Central)no datano datano data
Michael Dwyer
President of Regional Operations (South-Central)no datano datano data
Nanette Sanders
Senior Vice President of Operationsno datano datano data
Linda Chen
President of Regional Operations (West)2.4yrsno datano data

2.7yrs

Average Tenure

61.5yo

Average Age

Experienced Management: MD's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Swift
CEO & Director1.5yrsUS$2.24m0.20%
$ 1.8m
Mark Ordan
Chair4.2yrsUS$554.45k0.20%
$ 1.8m
Guy Sansone
Lead Independent Director4.2yrsUS$295.00k0.081%
$ 721.4k
Thomas McEachin
Independent Director4.2yrsUS$252.50k0.065%
$ 577.0k
Sylvia Young
Independent Director1.3yrsUS$201.00k0.035%
$ 308.2k
John Starcher
Independent Director4.2yrsUS$230.00k0.065%
$ 576.9k
Shirley Weis
Independent Director4.2yrsUS$245.00k0.043%
$ 380.4k
Gavin Molinelli
Board Observer4.2yrsno datano data
Michael Rucker
Independent Director5.3yrsUS$242.50k0.069%
$ 614.1k
Laura Linynsky
Independent Director2.3yrsUS$230.00k0.023%
$ 205.3k

4.2yrs

Average Tenure

61yo

Average Age

Experienced Board: MD's board of directors are considered experienced (4.2 years average tenure).